Skip to main content

EGFR Archives

VUMC scientists discover key step to kidney fibrosis

Nov. 21, 2023—Researchers at Vanderbilt University Medical Center for the first time have shown that activation of the epidermal growth factor receptor (EGFR) is essential for the development of kidney fibrosis, tissue scarring following injury that can lead to kidney failure.

Read more


VUMC adopts updated kidney function equation to better guide patient care decisions

Nov. 17, 2022—In December Vanderbilt University Medical Center will again update the equation used for estimating kidney function with the goals of improving health equity and better guiding patient care decisions.

Read more


Study supports removing race from estimate of kidney function

Nov. 17, 2022—An in-depth analysis by Vanderbilt investigators of published research studies supports removing race from the calculation of estimated glomerular filtration rate (eGFR) — an assessment of kidney function.

Read more


Inflammatory driver of obesity

Aug. 25, 2022—Blocking the EGF receptor signaling pathway in immune system macrophages represents a new target for improving insulin resistance in people with obesity.

Read more


Study reveals need for matching targeted therapies with EGFR subtypes

Jul. 28, 2022—A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.

Read more


New prognosis predictor and target for gastric cancer

Apr. 7, 2022—The protein CGA — a subunit of glycoprotein hormones — is a biomarker that predicts chemoresistance in gastric cancer and could be targeted along with EGFR to restore chemosensitivity.

Read more


The role of polarity in early cancer

Sep. 21, 2021—Mutations in the protein epiregulin, an EGF receptor ligand, affect larger epithelial cell reorganization and may contribute to early cancer development, Vanderbilt researchers discovered.

Read more


Blocking tumor ‘signals’ and ‘fuel’

Aug. 25, 2020—Combining two drugs reduced colorectal cancer cell growth in vitro and in an animal model, suggesting the combination may be a promising treatment for patients.

Read more


Protein study may be key to treating fibrotic diseases

Jul. 30, 2020—A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently.

Read more


Group’s efforts lead to removal of race as a variable in common test of kidney function

Jul. 13, 2020—A group of Vanderbilt students, residents and faculty — connected through their passion for health equity — have identified and worked together to rectify longstanding concerns about the inappropriate use of race as a variable in the calculation of estimated glomerular filtration rate (eGFR), which estimates a patient’s level of kidney function and helps determine the stage of kidney disease.

Read more


Sex differences in kidney injury

Jul. 25, 2019—Men are more susceptible to progressive kidney disease than women; new VUMC studies point to differences in the expression and activation of the EGF receptor.

Read more


Targeting diabetic kidney disease

Oct. 12, 2018—Pathways activated by the epidermal growth factor receptor may be attractive targets to treat diabetic kidney disease, according to new findings from Vanderbilt investigators.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more